Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.
about
The influence of Myrj 59 on the solubility, toxicity and activity of amphotericin BImprovement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomesInhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micellesLimited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in ratsIn vivo efficacy of a synthetic coumarin derivative in a murine model of aspergillosisA liposomal MRI contrast agent: phosphatidylethanolamine-DTPA.Comparative evaluation of two membrane-based liposomal MRI contrast agents.Bicosomes: bicelles in dilute systems.Unusual lipid structures selectively reduce the toxicity of amphotericin B.Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumorsAn optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasisCharacterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patientsEffect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis.Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids.Amphotericin B: delivery systems.Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes.Carrier effects on biological activity of amphotericin B.In vitro models for studying toxicity of antifungal agentsInfluence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability.Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose.Amphotericin B lipid complex therapy of experimental fungal infections in miceLiposomal amphotericin B inhibits in vitro T-lymphocyte response to antigenComparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.Effects of the aggregation state of amphotericin B on its toxicity to mice.Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.Optimizing efficacy of amphotericin B through nanomodification.Optimizing efficacy of Amphotericin B through nanomodification.Drug delivery systems in the treatment of African trypanosomiasis infections.New approaches from nanomedicine for treating leishmaniasis.Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin.Chemotherapy of leishmaniasis: present challenges.Drug delivery to macrophages for the therapy of cancer and infectious diseases.Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis.Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.Liposomal amphotericin B bases of therapeutic index increase.
P2860
Q28322976-AAF609E2-05DB-4E03-BFF3-D92A583D3CD7Q28328605-0F15D73F-B6E6-4945-81CA-53911B428453Q28328856-FF90BF4A-6BC5-462C-9697-6EDA9DD0BEDEQ28333669-599FE9A2-1C9D-43CA-B395-EC15AFFEB1ABQ28542402-D5A8C40F-E01B-4059-9769-0DDB69DD4018Q31139828-422CB180-C275-4E5D-B7C9-4B4711BC13D7Q33577244-77910D62-1EBC-46EE-806F-73B2E538CC23Q33636209-F0DEC871-3C89-4F70-9D29-D5F62906F6CFQ33641360-EE74ACE6-7994-448C-998D-4C8F54A20126Q33649082-B33E3329-4FD8-4224-8DA0-49C51735ADD6Q34565059-40DB7B69-CFF5-40E4-A9BE-3A934FE49A21Q34763371-79D2721D-9441-4363-BAFB-9A2A289DA33CQ35136556-35204F13-1152-4F88-AA81-077345E053F1Q35243361-0BB93EB1-B5C6-4331-B170-9DDF93CCE905Q35244905-BDCEE81E-D1FA-4827-BA38-EB9D1B827D11Q35249721-E0A8E21B-C477-49B8-A3E7-F3B075EC9E0AQ35309077-8EC14F8D-0756-413C-B113-763E29D877A9Q35372581-2F56820A-7E8C-4EAC-9093-4CC744D8E155Q35447528-31C5DE42-1433-41D0-8947-E1EB050730BBQ35824054-F30C98F0-4E6B-4281-BBE6-BA4FED24034BQ36379940-C107F6F7-B570-4BB4-B213-60E4647FA31BQ36752486-73ACE2BD-5D5E-4BC2-B0F5-42261797C354Q36753279-FBC6B622-B417-4DCB-80B4-D47C6C18810AQ36753723-5A47014B-2113-43A9-AE26-A3459477B047Q36754865-EFF63B3F-C353-43D2-A596-72255EAF5EF9Q36757947-B3232DAC-D6F2-45D7-AED9-81F0ABAF9AC8Q36758184-DBDBD816-778F-4CD3-B5C4-AA1BF1CC49A4Q36920328-C58E857C-2901-46E9-8973-5DF6C509B21CQ37178176-C8EA15DC-82D2-4466-B058-4C80B5600282Q37876880-244AE289-3B13-4366-95E1-A694BC5FC448Q38612712-EDA39345-3E8F-401B-A16D-28C0355A4B56Q38767228-1046A3AA-9270-4865-995C-1EAEB5E207BFQ39011875-B3CB77EC-53DD-4499-B73B-1DC6E1E13C40Q39696541-1CCE65E9-45C3-4871-BB8C-69DCB6067AD1Q39819915-2F8BC3F5-8B81-49AE-A6E6-E7251F0BFE52Q39868009-5496C591-CA30-4608-8F8F-8C3CD211C7FBQ40085689-037EB0F2-88C3-40D4-B2AB-011E1F7EFC75Q40087802-7F58E06E-FF1C-462C-9C4B-8A53BA223203Q40166247-83B2B5D3-E5A9-41B5-BA2C-1B7D19A884A2Q40859578-8A65B24F-0123-4E20-B026-7017D0637422
P2860
Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.
description
1987 nî lūn-bûn
@nan
1987 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի մարտին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Effect of lipid composition an ...... e-intercalated amphotericin B.
@ast
Effect of lipid composition an ...... e-intercalated amphotericin B.
@en
type
label
Effect of lipid composition an ...... e-intercalated amphotericin B.
@ast
Effect of lipid composition an ...... e-intercalated amphotericin B.
@en
prefLabel
Effect of lipid composition an ...... e-intercalated amphotericin B.
@ast
Effect of lipid composition an ...... e-intercalated amphotericin B.
@en
P2093
P2860
P356
P1476
Effect of lipid composition an ...... e-intercalated amphotericin B.
@en
P2093
P2860
P304
P356
10.1128/AAC.31.3.421
P407
P577
1987-03-01T00:00:00Z